Sanofi’s Eledon Pharmaceuticals ELDN Stock Holding History

Sanofi’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-814,980	Closed	-$2.51M	–	11
2026 Q1	$2.51M	Hold	814,980	–	–	0.75%	8
2025 Q4	$1.23M	Hold	814,980	–	–	0.4%	7
2025 Q3	$2.11M	Hold	814,980	–	–	0.81%	8
2025 Q2	$2.21M	Hold	814,980	–	–	1.26%	7
2025 Q1	$2.76M	Hold	814,980	–	–	1.66%	5
2024 Q4	$3.36M	Buy	+814,980	New	+$3.21M	1.93%	6

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Sanofi's ELDN Position: Q2 2026 in Review

Sanofi sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 814,980 shares — an estimated $2.51M sold.

Sanofi first reported a position in ELDN in Q4 2024 and held it in 6 quarters. The position peaked at $3.36M in Q4 2024. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Sanofi reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sanofi sold 814,980 Eledon Pharmaceuticals shares in Q2 2026, an estimated $2.51M.
Sanofi first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Sanofi's Eledon Pharmaceuticals position peaked at $3.36M in Q4 2024.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Sanofi's 13F filing for Q2 2026, filed 28 Jul 2026.